about
Coronary vascular dysfunction and prognosis in patients with chronic kidney disease.Increased concentration of circulating angiogenesis and nitric oxide inhibitors induces endothelial to mesenchymal transition and myocardial fibrosis in patients with chronic kidney disease.Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fractionArrhythmia and Sudden Death in Hemodialysis Patients: Protocol and Baseline Characteristics of the Monitoring in Dialysis StudyHow is the heart best protected in chronic dialysis patients?: Between Scylla and Charybdis: what is the appropriate role for percutaneous coronary revascularization and coronary artery bypass grafting in patients on dialysis?Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease.Cardiovascular complications in chronic dialysis patients.A Decision-Making Algorithm for Initiation and Discontinuation of RRT in Severe AKI.The Use of a Multidimensional Measure of Dialysis Adequacy-Moving beyond Small Solute Kinetics.Percutaneous Coronary Intervention Versus Optimal Medical Therapy for Stable Angina in Advanced CKD: A Decision Analysis.Reduced risk of myocardial infarct and revascularization following coronary artery bypass grafting compared with percutaneous coronary intervention in patients with chronic kidney disease.Epidemiology and Natural History of the Cardiorenal Syndromes in a Cohort with Echocardiography.Association of circulating angiogenesis inhibitors and asymmetric dimethyl arginine with coronary plaque burden.Shades of grey: the conundrum of implantable defibrillators in individuals with advanced CKDDo implantable defibrillators help patients with CKD?Early versus late initiation of renal replacement therapy in patients with acute kidney injury: a meta-analysis of randomised clinical trials.Coronary flow reserve is predictive of the risk of cardiovascular death regardless of chronic kidney disease stage.Association of activated vitamin D use with myocardial fibrosis and capillary supply: results of an autopsy study.Spironolactone in Dialysis: What's Old Is New Again.ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD.Echocardiographic parameters and renal outcomes in patients with preserved renal function, and mild- moderate CKD.Introduction: Cardiovascular Disease in Chronic Kidney DiseaseComparative Utilization and Temporal Trends in Cardiac Stress Testing in U.S. Medicare Beneficiaries With and Without Chronic Kidney DiseaseAccelerated Venovenous Hemofiltration as a Transitional Renal Replacement Therapy in the Intensive Care UnitThe axis of local cardiac endogenous Klotho-TGF-β1-Wnt signaling mediates cardiac fibrosis in humanChronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies ConferenceDuration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-AnalysisEnd-Stage Renal Disease and Arrhythmic DeathChronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art ReviewLong-term outcomes of patients with stable coronary disease and chronic kidney dysfunction: 10-year follow-up of the Medicine, Angioplasty, or Surgery Study II TrialAssociation of Changes in Creatinine and Potassium Levels After Initiation of Renin Angiotensin Aldosterone System Inhibitors With Emergency Department Visits, Hospitalizations, and Mortality in Individuals With Chronic Kidney DiseaseMetformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney diseaseIdentification of ESRD in Cardiovascular Procedural DatabasesEvaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE TrialExtracorporeal Stromal Cell Therapy for Subjects With Dialysis-Dependent Acute Kidney InjuryCoronary Microvascular Dysfunction, Left Ventricular Remodeling, and Clinical Outcomes in Patients With Chronic Kidney ImpairmentCanagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention GroupsEfficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER TrialComparative Effectiveness of Medical Therapy, Percutaneous Revascularization, and Surgical Coronary Revascularization in Cardiovascular Risk Subgroups of Patients With CKD: A Retrospective Cohort Study of Medicare Beneficiaries
P50
Q30448743-E8221D96-2E46-4B2B-9CFA-21BD55239494Q34166007-B2542122-5746-48B3-82A2-F1B43F2316B8Q35995478-EE40A41F-E815-4D73-A783-98C176F9F7D7Q36737143-6CB97E53-217D-43C3-97BC-2A71287A12BBQ36770929-B5B13F0E-C232-45D3-B6D0-60524FEA02D0Q38179487-92582225-1203-49D1-B346-ECD8BC4BEE44Q38258133-84849C5E-72CA-4F8F-BEED-241F37D8F558Q38956399-2710D733-B522-4714-831D-BDCCD1ECCBE9Q39001160-F5D658AF-9FA1-4834-900B-F25568B0242EQ39185404-64E996DF-724C-4794-9F8B-E6B3BFE386CCQ39373204-B3872046-CA22-4B43-BE12-C7783A700809Q39711593-4F3997AF-F345-4488-BD49-38863A5068D3Q40085514-C97B52E5-34BF-43BB-ADE1-755C4D4FD01FQ42287888-D0B35D5C-33C8-451B-A8C6-058CEA5D9157Q42362485-70E8E63D-AC46-4E56-9F32-B8AF8F5DC4C9Q42767794-8B05E2F7-3FA6-4F71-938F-E14100763192Q47778416-00C7C0E0-8C36-4081-B3F8-852340B16623Q47792905-483ABF26-17D7-424F-AAFD-7F732BA77D28Q48749517-A3936778-E2DD-453A-BE89-332023F0C76AQ54374997-40FE6545-6256-4FF5-A2BD-4CDCA6DCF417Q54563569-2A13BA12-4B90-4673-A2E7-B64C2C91F16DQ55628123-0B363832-5E07-4AAE-BC7D-C145B2272D0EQ58578177-5488BA88-40FC-4580-AF41-0C407A219319Q89125764-658035F3-C2A3-44E9-A5B7-06EDCD9FCDB6Q89878052-B56FEA33-DD9B-42EA-815F-D786C34D4542Q90104612-0EE6552E-81A8-45FC-B315-11C1A148FBCAQ90204240-16ABA361-2754-483A-9AA3-248CC4572B70Q90213322-F7F823BF-9DC7-43FF-A7D9-703DB97D4334Q90345523-81EC0B5C-20F0-47D8-A068-DB54DBE334E6Q90464373-72978041-81EB-417E-9BB4-123CB67329DEQ90780380-4432A0A3-04A6-447D-97BE-E66D8B80C1E0Q91058256-9598BAEE-5094-4625-8AB2-5BD706939B45Q91174545-EAC166E8-4C01-4519-97C5-1B0682C13735Q91178726-7657195B-FB16-4605-8EAC-88D69FE984A8Q91213374-BE80B26F-F1C5-48EC-9DA1-5B4F850C2C94Q91349983-0A27163C-5299-45F1-AFDA-F2979C128A7FQ91516679-0E02AC4E-3831-4EE3-A34A-36910037F7A4Q91772310-250C290A-5E09-4352-9CC1-1554FD3A94C4Q92729302-F9C9B81D-4062-426C-B057-3044EFA0FED8Q93126949-525452CF-7904-4A7E-8C50-0DFB5A9C8359
P50
description
investigador
@es
researcher
@en
name
David M Charytan
@en
type
label
David M Charytan
@en
prefLabel
David M Charytan
@en
P31
P496
0000-0002-7695-3583